Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in persistent/recurrent ovarian cancer
NCT00721162Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2008
- Primary completion
- May 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants With Progression-Free Survival at 6 Months and Objective Response Rate up to 34.6 months. Started Aug 2008; status: completed.
02
Drugs
ramucirumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00721162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00721162.